SALT LAKE CITY, Oct. 21, 2013 /PRNewswire/ -- Vital Access Corporation today announced that Dr. William Jennings will present results from the recently completed U.S. SAVE study, an IDE pivotal trial of the VWING™ Vascular Needle Guide, at the 2013 CIDA Meeting in San Francisco. Dr. Jennings, who was a principal investigator for the SAVE study at the St. John Medical Center in Tulsa, is scheduled to present at the 'New Technology on the Horizon' session, held on Friday, October 25, 2013 at 7:30am . Dr. Jennings will also discuss VWING surgical techniques and cannulation practice.

The SAVE study was a multi-center, AV fistula salvage trial that included 54 dialysis patients with uncannulatable, deep AV fistulae, who were implanted with VWINGs (82 devices were implanted in total) and followed for 6 months post-implantation. The robust clinical evidence generated from the SAVE study supported the recent U.S. market clearance of the VWING.

About Vital Access™:

Vital Access Corporation is a privately held company located in Salt Lake City that designs and manufactures surgical and interventional technologies to improve vascular access for patients and caregivers. The VWING™ Vascular Needle Guide is commercially available in the U.S., Europe, Canada, and New Zealand. For more information, call 801-433-9390 or visit www.vital-access.com .

CONTACT: Doug Smith, 801-433-9390

SOURCE Vital Access Corporation

RELATED LINKS http://www.vital-access.com